COVID-19: Abnormal liver function tests

被引:691
作者
Cai, Qingxian [1 ]
Huang, Deliang [1 ]
Yu, Hong [1 ]
Zhu, Zhibin [1 ]
Xia, Zhang [1 ]
Su, Yinan [1 ]
Li, Zhiwei [1 ]
Zhou, Guangde [1 ]
Gou, Jizhou [1 ]
Qu, Jiuxin [1 ]
Sun, Yan [1 ]
Liu, Yingxia [1 ]
He, Qing [1 ]
Chen, Jun [1 ]
Liu, Lei [1 ]
Xu, Lin [2 ]
机构
[1] Southern Univ Sci & Technol, Natl Clin Res Ctr Infect Dis, Peoples Hosp Shenzhen 3, Affiliated Hosp 2, Shenzhen 518100, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China
关键词
2019-nCoV; SARS-Cov-2; Pneumonia; Critical care; Liver injury; Liver tests; Bilirubin; PNEUMONIA;
D O I
10.1016/j.jhep.2020.04.006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver test results. Methods: Clinical records and laboratory results were obtained from 417 patients with laboratory-confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information on clinical features of patients with abnormal liver tests were collected for analysis. Results: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients having alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase levels elevated to more than 3x the upper limit of normal, respectively. Patients with abnormal liver tests of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios [ORs] 2.73; 95% CI 1.19-6.3, and 4.44, 95% CI 1.93-10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both p <0.01). Conclusion: Patients with abnormal liver tests were at higher risk of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, which should be monitored and evaluated frequently. Lay summary: Data on liver tests in patients with COVID-19 are scarce. We observed a high prevalence of liver test abnormalities and liver injury in 417 patients with COVID-19 admitted to our referral center, and the prevalence increased substantially during hospitalization. The presence of abnormal liver tests and liver injury were associated with the progression to severe pneumonia. The detrimental effects on liver injury were related to certain medications used during hospitalization, which warrants frequent monitoring and evaluation for these patients. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:566 / 574
页数:9
相关论文
共 33 条
  • [11] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
    Lampertico P.
    Agarwal K.
    Berg T.
    Buti M.
    Janssen H.L.A.
    Papatheodoridis G.
    Zoulim F.
    Tacke F.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 67 (02) : 370 - 398
  • [12] Alkaline phosphatase: beyond the liver
    Fernandez, Nicole J.
    Kidney, Beverly A.
    [J]. VETERINARY CLINICAL PATHOLOGY, 2007, 36 (03) : 223 - 233
  • [13] Clinical Characteristics of Coronavirus Disease 2019 in China
    Guan, W.
    Ni, Z.
    Hu, Yu
    Liang, W.
    Ou, C.
    He, J.
    Liu, L.
    Shan, H.
    Lei, C.
    Hui, D. S. C.
    Du, B.
    Li, L.
    Zeng, G.
    Yuen, K. -Y.
    Chen, R.
    Tang, C.
    Wang, T.
    Chen, P.
    Xiang, J.
    Li, S.
    Wang, Jin-lin
    Liang, Z.
    Peng, Y.
    Wei, L.
    Liu, Y.
    Hu, Ya-hua
    Peng, P.
    Wang, Jian-ming
    Liu, J.
    Chen, Z.
    Li, G.
    Zheng, Z.
    Qiu, S.
    Luo, J.
    Ye, C.
    Zhu, S.
    Zhong, N.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (18) : 1708 - 1720
  • [14] SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
    Hoffmann, Markus
    Kleine-Weber, Hannah
    Schroeder, Simon
    Krueger, Nadine
    Herrler, Tanja
    Erichsen, Sandra
    Schiergens, Tobias S.
    Herrler, Georg
    Wu, Nai-Huei
    Nitsche, Andreas
    Mueller, Marcel A.
    Drosten, Christian
    Poehlmann, Stefan
    [J]. CELL, 2020, 181 (02) : 271 - +
  • [15] Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis
    Jia, Zhihui
    Yan, Liming
    Ren, Zhilin
    Wu, Lijie
    Wang, Jin
    Guo, Jing
    Zheng, Litao
    Ming, Zhenhua
    Zhang, Lianqi
    Lou, Zhiyong
    Rao, Zihe
    [J]. NUCLEIC ACIDS RESEARCH, 2019, 47 (12) : 6538 - 6550
  • [16] Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
    Lu, Roujian
    Zhao, Xiang
    Li, Juan
    Niu, Peihua
    Yang, Bo
    Wu, Honglong
    Wang, Wenling
    Song, Hao
    Huang, Baoying
    Zhu, Na
    Bi, Yuhai
    Ma, Xuejun
    Zhan, Faxian
    Wang, Liang
    Hu, Tao
    Zhou, Hong
    Hu, Zhenhong
    Zhou, Weimin
    Zhao, Li
    Chen, Jing
    Meng, Yao
    Wang, Ji
    Lin, Yang
    Yuan, Jianying
    Xie, Zhihao
    Ma, Jinmin
    Liu, William J.
    Wang, Dayan
    Xu, Wenbo
    Holmes, Edward C.
    Gao, George F.
    Wu, Guizhen
    Chen, Weijun
    Shi, Weifeng
    Tan, Wenjie
    [J]. LANCET, 2020, 395 (10224) : 565 - 574
  • [17] Preparing for the Most Critically Ill Patients With COVID-19 The Potential Role of Extracorporeal Membrane Oxygenation
    MacLaren, Graeme
    Fisher, Dale
    Brodie, Daniel
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (13): : 1245 - 1246
  • [18] Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients:: evaluation of risk factors for liver enzyme elevation
    Meraviglia, P
    Schiavini, M
    Castagna, A
    Viganò, P
    Bini, T
    Landonio, S
    Danise, A
    Moioli, MC
    Angeli, E
    Bongiovanni, M
    Hasson, H
    Duca, P
    Cargnel, A
    [J]. HIV MEDICINE, 2004, 5 (05) : 334 - 343
  • [19] Diagnosis and Treatment of Adults with Community-acquired Pneumonia An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America
    Metlay, Joshua P.
    Waterer, Grant W.
    Long, Ann C.
    Anzueto, Antonio
    Brozek, Jan
    Crothers, Kristina
    Cooley, Laura A.
    Dean, Nathan C.
    Fine, Michael J.
    Flanders, Scott A.
    Griffin, Marie R.
    Metersky, Mark L.
    Musher, Daniel M.
    Restrepo, Marcos, I
    Whitney, Cynthia G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 200 (07) : E45 - E67
  • [20] *NAT HLTH COMM PEO, HDB PREV TREATM PNEU